Clovis Oncology Inc. [CLVS] insider makes an insider purchase of 4,807 shares worth 7024.0.

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Clovis Oncology Inc. shares valued at $7,024 were sold by Gross Paul Edward on Aug 02. At $1.46 per share, Gross Paul Edward sold 4,807 shares. The insider’s holdings dropped to 87,601 shares worth approximately $0.14 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Also, IVERS-READ GILLIAN C sold 3,802 shares, netting a total of over 5,555 in proceeds. Following the sale of shares at $1.46 each, the insider now holds 283,565 shares.

Before that, Rolfe Lindsey had sold 4,330 shares from its account. In a trade valued at $6,326, the insider traded Clovis Oncology Inc. shares for $1.46 each. Upon closing the transaction, the insider’s holdings decreased to 4,330 shares, worth approximately $0.17 million.

As published in a research note from H.C. Wainwright on May 06, 2022, Clovis Oncology Inc. [CLVS] has been rated down from a Buy to a Neutral. Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in mid May. As of April 27, 2020, SVB Leerink has decreased its “Mkt perform” rating to a “an Underperform” for CLVS. Earlier on April 09, 2020, BofA/Merrill downgraded its rating. Their new recommendation was “an Underperform” for CLVS stock which previously was a “a Neutral”.

Analyzing CLVS’s Price Performance

On Thursday, Clovis Oncology Inc. [NASDAQ: CLVS] plunged -0.61% to $1.64. The stock’s lowest price that day was $1.62, but it reached a high of $1.79 in the same session. During the last five days, there has been a drop of approximately -5.75%. Over the course of the year, Clovis Oncology Inc. shares have dropped approximately -39.48%. Shares of the company reached a 52-week high of $3.2500 on 07/08/22 and a 52-week low of $0.5810 on 06/13/22. A 50-day SMA is recorded $1.5219, while a 200-day SMA reached $2.2329. Nevertheless, trading volume fell to 3.46 million shares from 3.5 million shares the previous day.

Support And Resistance Levels for Clovis Oncology Inc. (CLVS)

According to the 24-hour chart, there is a support level at 1.5767, which, if violated, would cause prices to drop to 1.5133. In the upper region, resistance lies at 1.7467. The next price resistance is at 1.8533. RSI (Relative Strength Index) is 45.46 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.1250, which suggests the price will decrease in the coming days. Percent R is at 75.95%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Clovis Oncology Inc. subject to short interest?

Stocks of Clovis Oncology Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -12.67 million shares to 28.58 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 41.25 million shares. A decline of -44.33% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 1.08 of the overall float, the days-to-cover ratio (short ratio) decline to 1.08.

Which companies own the most shares of Clovis Oncology Inc. (CLVS)?

According to The Vanguard Group, Inc. filings, the company currently owns 12,073,240 shares, which is about 8.39% of the total CLVS shares outstanding. The investor’s shares have appreciated by 2,252,669 from its previous 13-F filing of 9820571.0 shares. With the completion of the buy transaction, BlackRock Fund Advisors’s stake is now worth $15,381,065. Palo Alto Investors LP acquire a 11.91% interest valued at $8.05 million while Millennium Management LLC purchased a 2,525,471 stake. A total of -13,495,065 shares of Clovis Oncology Inc. were bought by SSgA Funds Management, Inc. during the quarter, and -115,914 were sold by Geode Capital Management LLC. In its current portfolio, Renaissance Technologies LLC holds 1,459,900 shares valued at $2.63 million.

In terms of Clovis Oncology Inc. share price expectations, FactSet research, analysts set an average price target of $3.00 in the next 12 months, up nearly 81.82% from the previous closing price of $1.65. Analysts anticipate Clovis Oncology Inc. stock to reach $3.00 by 2022, with the lowest price target being $3.00. In spite of this, 3 analysts ranked Clovis Oncology Inc. stock as a Hold at the end of 2022. On January 08, 2020, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $27.


Please enter your comment!
Please enter your name here